文献速递角膜与眼表疾病眼底病与葡萄膜炎

尼达尼布滴眼液经RAP1/MEK/ERK通路抑制碱烧伤角膜新生血管

Nintedanib Eye Drops Inhibit Alkali Burn-Induced Corneal Neovascularization Via RAP1/MEK/ERK Signaling Pathway.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究在体外用人脐静脉内皮细胞(HUVEC)评估尼达尼布(NTD)对增殖、迁移和管样结构形成的作用,并通过RNA测序与蛋白检测探索机制;同时建立小鼠角膜碱烧伤新生血管(CNV)模型,局部滴用NTD每日三次连续10天。结果显示NTD在体外抑制HUVEC增殖、迁移和管样结构形成,在体内减轻CNV、炎症及角膜LYVE1、CD31、VEGFA、RAP1表达,机制与RAP1/MEK/ERK通路相关。

要点

  • NTD滴眼液可减轻碱烧伤诱导的小鼠角膜新生血管与炎症。
  • 体外NTD抑制VEGF刺激的HUVEC增殖、迁移和管样结构形成。
  • 机制涉及RAP1/MEK/ERK通路及HIF-1α、VEGFA、VEGFR2下调。

核心结论

  • 局部应用NTD可有效减轻碱烧伤诱导的角膜新生血管,其作用与RAP1/MEK/ERK通路相关。
  • NTD可能是碱烧伤后角膜新生血管的有效治疗策略。

研究设计与样本

  • 体外实验采用人脐静脉内皮细胞(HUVEC)进行增殖、迁移和管样结构形成检测。
  • 通过RNA测序识别NTD处理后的差异表达基因,并用免疫荧光和western blotting评估RAP1A/MEK/HIF-1α轴。
  • 建立小鼠角膜碱烧伤新生血管模型,局部滴用NTD滴眼液每日三次、连续10天。
  • 建模后第3天和第7天行HE染色和免疫荧光,第10天心脏灌注后定量分析角膜新生血管。

主要发现

  • 体外NTD抑制HUVEC的增殖、迁移和管样结构形成。
  • RNA测序分析富集到RAP1和MAPK信号通路。
  • NTD下调VEGF刺激的HUVEC中RAP1A、p-MEK、p-ERK1/2、HIF-1α、VEGFA和VEGFR2的表达。
  • 体内NTD滴眼液具有适当的渗透压和pH值。
  • 与对照和溶剂组相比,NTD滴眼液抑制角膜新生血管、炎症及角膜LYVE1、CD31、VEGFA和RAP1的表达。

临床怎么用

  • 结果提示局部NTD滴眼液可能用于碱烧伤后角膜新生血管的干预,但尚需临床研究验证。
  • 机制上可关注RAP1/MEK/ERK通路及VEGFA/VEGFR2、HIF-1α作为NTD作用的相关靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the effect of topical nintedanib (NTD) eye drops on alkali burn-induced corneal neovascularization (CNV) and the mechanisms involved. METHODS: The effects of NTD on the proliferation, migration, and tube-like structure formation assays were evaluated in human umbilical vein endothelial cells (HUVECs). RNA sequencing was performed to identify differentially expressed genes following NTD treatment. The expression of the RAP1A/MEK/HIF-1α axis was assessed by immunofluorescence (IF) and western blotting in HUVECs after NTD treatment. A CNV mouse model was established, and topically administered NTD eye drops three times daily for 10 consecutive days. Hematoxylin and eosin staining and IF were performed on days 3 and 7 after modeling. CNV was quantitatively analyzed after cardiac perfusion on day 10. RESULTS: In vitro, NTD inhibited the proliferation, migration, and tube-like structure formation of HUVECs. RAP1 and MAPK signaling pathways were enriched by RNA sequencing analysis. NTD downregulated the expressions of RAP1A, p-MEK, p-ERK1/2, HIF-1α, VEGFA, and VEGFR2 in VEGF-stimulated HUVECs. In vivo, NTD eye drops demonstrated appropriate osmolarity and pH values. Compared to the control and vehicle groups, NTD eye drops suppressed CNV, inflammation, and the expression of LYVE1, CD31, VEGFA, and RAP1 in the cornea. CONCLUSIONS: Topical NTD administration effectively reduced alkali burn-induced CNV, which was related to the RAP1/MEK/ERK pathway. NTD could be an effective treatment strategy for CNV post-alkali injury.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Li J, Zhang G, Li J, et al. Nintedanib Eye Drops Inhibit Alkali Burn-Induced Corneal Neovascularization Via RAP1/MEK/ERK Signaling Pathway. Invest Ophthalmol Vis Sci. 2026. PMID: 41854210. doi:10.1167/iovs.67.3.44

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。